CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type

CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type

(2014) Pengfei Li et al.   BMC CANCER

Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer/T cell lymphoma

(2014) Liang Wang et al.   LEUKEMIA & LYMPHOMA

Combination of gemcitabine, l-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up

(2014) Wang Liang et al.   MEDICAL ONCOLOGY

Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma

(2013) Junya Kuroda et al.   Expert Review of Anticancer Therapy

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type

(2013) Ningjing Lin et al.   Journal of Hematology & Oncology

Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor

(2013) Wang Liang et al.   MEDICAL ONCOLOGY

Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma

(2013) Liang Wang et al.   TUMOR BIOLOGY

First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma

(2012) Liang Wang et al.   CANCER

Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients

(2012) Liang Wang et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Phase 2 trial of “Sandwich”L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma

(2011) Ming Jiang et al.   CANCER

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

(2011) Motoko Yamaguchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience

(2011) Huiqiang Huang et al.   LEUKEMIA & LYMPHOMA

Expression of ezrin correlates with poor prognosis of nasopharyngeal carcinoma

(2011) Liang Wang et al.   TUMOR BIOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type

(2008) Biyun Wang et al.   AMERICAN JOURNAL OF HEMATOLOGY

CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment

(2008) P. E. M. Patten et al.   BLOOD

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY

Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: Elucidating the significance of systemic chemotherapy

(2007) Ye Guo et al.   ORAL ONCOLOGY